Abstract: A current cycle count associated with a memory sub-system is determined. The current cycle count is compared to a set of cycle count threshold levels to determine a current lifecycle stage of the memory sub-system. A temperature associated with the memory sub-system is measured. The temperature is compared to a set of temperature levels to determine a current temperature level of the memory sub-system. A write-to-read delay time corresponding to the current lifecycle stage and the current temperature level is determined.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: Disclosed herein are pharmaceutical compositions, comprising a therapeutically effective amount of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt thereof, and at least one protective agent, and uses thereof.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.

Abstract: The present invention involves compositions and methods for treating cancer using a combination of cell cycle modulating agent(s) and anticancer agents or therapies, particularly S-phase specific therapies.

Abstract: A tissue product is disclosed containing an additive composition. The additive composition may be, for instance, a composition designed to provide benefits to a user's skin. In accordance with the present disclosure, the additive composition is located in a target delivery zone on a base web. The base web is modified in the target delivery zone so that the additive composition more efficiently transfers to an opposing surface during use.

Abstract: The present invention is directed to a health-and-hygiene appliance comprising a dispersible component and a releasable component. Some or all of the releasable component is not homogeneously distributed throughout the dispersible component. Instead, the releasable component is disposed adjacent or proximate to the dispersible component, as would occur if the dispersible component was coated, sprayed, injected, deposited, printed, or otherwise associated with a formed dispersible component. One example of such an appliance is a cleansing product in which, on exposure to liquid, such as water, the dispersible component disperses or disintegrates, thereby releasing, and making available, all or substantially all of the releasable component, in this case a soap, cleanser, or other formulation. The releasable component may be released prior to, concurrent with, and/or after dispersal or disintegration of the dispersing component. The appliance can be sized for convenient handling by a caregiver or user—e.g.

Abstract: The present invention is directed to ion triggerable, water-dispersible cationic polymers. The present invention is also directed to a method of making ion triggerable, water-dispersible cationic polymers and their applicability as binder compositions. The present invention is further directed to fiber-containing fabrics and webs comprising ion triggerable, water-dispersible binder compositions and their applicability in water-dispersible personal care products, such as wet wipes.

Abstract: A patch is presented for use in conjunction with a surface, the patch including a backsheet having an adherent surface, wherein the backsheet is translucent; an outermost surface opposite the adherent surface; an adhesive applied to the adherent surface; a peel layer removably attached to the adhesive; and a malodor-reducing agent. A method for manufacturing a patch is presented, the method including producing a backsheet from a water-dispersible polymer; applying a malodor-reducing agent to the polymer; adding an adhesive to the backsheet; and adhering a peel strip to the adhesive.

Abstract: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.

Abstract: The present invention discloses a disposable cleaning product for use in household cleaning or personal care applications. The cleaning product of the invention is a multi-layer laminate product and may include at least two distinct layers, an abrasive layer and an absorbent layer. The absorbent layer contains a sponge-like member optionally in combination with a plurality of cellulosic fibrous webs. The sponge-like member can be made from various materials. For example, in one embodiment, the sponge-like member comprises one or more layers of a spunbond web containing crimped, bicomponent filaments.

Abstract: The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway.